tbuckley/cabot-search huggingface dataset:
AB0433 Quantiferon-Tb More Useful than Tuberculin Skin Test for Latent Tuberculosis Screening: A Hospital Experience
Authors: L. Sanchez Riera, N. Wilson, M. Al Izzi, I. Hussein, S. Nuhaily, N. Qahtani, N. Ibrahim, R. Aneja, T. Khan, S. Gonuguntla, H. Maashari, S. Waheeduddin, M. Al Maini
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The use of interferon gamma-release assays (IGRA) has become a very useful tool in the detection of latent tuberculosis (LTB) among patients on biological disease modifying anti-rheumatic drugs (bDMARDs). The IGRA offers some advantages over the intradermal tuberculin skin test (TST), such as, no requirement to re-schedule the patient for the test reading, the elimination of the inter-reader variability and higher specificity. These features facilitate the decision making when deciding which patients require tuberculosis (TB) chemoprophylaxis before starting bDMARDs, particularly in world regions with high incidence of vaccinated individuals and new TB cases. In our tertiary level hospital, the IGRA QuantiFERON-TB Test® (Cellestis Ltd, Australia), was introduced as routine screening test for LTB in late 2008 together with the usual chest X-ray, initially run concurrently and then substituting the old TST in most of the cases. <h3>Objectives</h3> In this report, we present the benefits of its use in decreasing the number of active TB cases among rheumatoid arthritis (RA) patients prescribed bDMARDs in our centre. <h3>Methods</h3> An audit was undertaken through the electronic medical record system of our hospital, which was implemented from January 2011 for all medical documentation. All RA patients aged 18 and over seen in the rheumatology outpatient clinic between Jan 2011 and September 2013 and on bDMARDs at any time during this period were identified. Among the cohort of RA patients on bDMARDs, we searched for patients with diagnosis of active TB or receiving anti-TB triple/quadruple therapy. Results were compared to previous RA cohort from the same hospital from the period 2003-2008, which was facilitated by two of the authors of this present paper who worked in our hospital during this period. <h3>Results</h3> Ninety-seven individuals diagnosed with RA and treated with any of the bDMARDs available during the study period were found. There were no documented cases of TB or active TB treatment among the 97 individuals on bDMARDs during the 34-month audit period. This contrasts with the three cases of TB reactivation among the 86 patients who received bDMARDs in our centre from 2003 to 2008. <h3>Conclusions</h3> Our data suggest that the IGRA QuantiFERON-TB Test® is more useful than the TST for the LTB screening in adult population on bDMARDs. This is particularly important in mixed populations with a high percentage of individuals being nationals from endemic countries in TB. Our recommendation is to systematically use IGRA in such settings, repeating this on an annual basis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5158
Demonstration of Subclinical Inguinal Hernia by Peritoneal Scintigraphy
Authors: SHIV M. GUPTA, SANJEEV BAGGA, NELSON GELFMAN, RICHARD MARGULES
Journal: Clinical Nuclear Medicine (1997)

Continuous ambulatory peritoneal dialysis is a reliable and practical method of treatment for chronic renal failure. However, it may occasionally be complicated by abdominal and inguinal hernias. Radionuclide peritoneal scanning may detect their presence even before they become clinically evident. The following case shows the unique contribution of peritoneal scintigraphy in establishing the diagnosis of a subclinical inguinal hernia in a patient on CAPD, thus leading to its effective management.
P997 NON SUPERIORITY OF DRUG-ELUTING BEADS WITH RESPECT TO CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A PROPENSITY SCORE ANALYSIS
Authors: A. Facciorusso, C. Sposito, L. Mariani, C. Spreafico, A. Marchianò, S. Bhoori, M. Barone, V. Mazzaferro
Journal: Journal of Hepatology (2014)
Abstract 1396: Bradykinin enhances cell migration in human prostate carcinoma cells via bradykinin B2 receptor, PKCdelta, c-Src and NF-kappaB signaling pathways
Authors: Hsin-Shan Yu, Chih-Hsin Tang
Journal: Cancer Research (2011)

Abstract Bradykinin (BK) is an inflammatory mediator, and shows elevated levels in regions of severe injury and inflammatory diseases. In addition, bradykinin has been found in many tumor cell lines and has been shown to be involved in carcinogenesis and cancer progression. Prostate cancer is the most common cancer excluding skin cancer in men and usually metastasizes to the particular organs in the late stages of cancer processes. The matrix metalloproteinase (MMP) play an important role in tissue remodeling associated with various physiological and pathological processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis and metastasis. In this study, we found that bradykinin increased the migration and the expression of MMP-9 in human prostate cancer cells (PC3,DU145 and LNCaP). Bradykinin-mediated migration and matrix MMP-9 up-regulation was attenuated by bradykinin B2 receptor antagonist (HOE140), protein kinase Cdelta (PKCdelta) inhibitor (Rottlerin), c-Src inhibitor (PP2), NF-kappaB inhibitor (PDTC), and IkappaB protease inhibitor (TPCK). Transfection of cells with bradykinin B2 receptor and protein kinase Cdelta (PKCdelta), siRNA or dominant-negative mutant of c-Src, IkappaBalpha kinase alpha(IKK alpha) and IkappaBalpha kinase beta(IKK beta), also inhibited the potentiating action of bradykinin. Stimulation of PC3 cells with bradykinin induced PKCdelta, c-Src, IKK alpha/beta, IkappaB and p65 phosphorylation, and kappaB-luciferase activity. In addition, BKR2 PCKdelta and c-Src pathways are involved in bradykinin-induced NFkappaB activation. Taken together, our results suggest that bradykinin enhances the migration of prostate carcinoma cells by increasing MMP9 expression through the bradykinin B2 receptor /PKCdelta/c-Src/NF-kappaB signal transduction pathways. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1396. doi:10.1158/1538-7445.AM2011-1396
P168 Reduced Gas Transfer (tlco) Predicts Poor Outcome In Patients With Pulmonary Hypertension And Heart Failure With Preserved Ejection Fraction
Authors: N. Hussain, S. Ramjug, C. Billings, J. Hurdman, C. Elliot, R. Condliffe, D. Kiely
Journal: Thorax (2014)

<h3>Rationale</h3> There is limited data on predictors of survival in patients with Pulmonary Hypertension (PH) in the context of Heart Failure and Preserved Ejection Fraction (HF-pEF). Simple non-invasive tests to aid the physician in prognostication would be valuable. The aim of this study was to examine demographic and non-invasive predictors of outcome in PH-HF-pEF in a large well phenotyped PH registry. <h3>Method</h3> In the ASPIRE Registry (Hurdman J <i>et al</i> Eur Resp J, 2012), 1737 consecutive, incident, treatment-naıve patients with suspected PH underwent diagnostic evaluation between February 2001 and 2010. Patients were diagnosed as PH-HF-pEF if no other causes of PH could be identified and they fulfilled the following criteria: signs and symptoms of heart failure; mean pulmonary artery pressure ≥25 mmHg at rest and pulmonary arterial wedge pressure &gt;15 mmHg by RHC; preserved left ventricular systolic function (ejection fraction ≥50%) by echocardiography or CMR. Predictors of survival were assessed using forward stepwise Cox regression analysis. Variables with a p-value <h3>Results</h3> 98 patients who fulfilled the diagnostic criteria for PH-HF-pEF were identified. Maximum duration of follow-up was 10 years with a mean follow up 4.9 ± 2.3 years, during which 33 (34%) patients died. After multivariate analysis, only ISWT distance HR 0.99 CI (0.99–1.00) and TLCO HR 0.96 CI(0.94–0.98) at baseline, were predictors of outcome (p &lt; 0.01). Median predicted TLCO in the PH-HF-pEF population was 65%. The 5-year survival in those with a TLCO &lt;65% predicted was 60%, compared with 85% in those whose TLCO was ≥65% (p &lt; 0.01). <h3>Conclusions</h3> Simple non-invasive testing such as TLCO and exercise capacity measured by the ISWT predict outcome in patients with PH-HF-pEF.
Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"?
Authors: R J Mayer
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.10.1532 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3049948 Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"? R J MayerxR J MayerSearch for articles by this author Show More Dana-Farber Cancer Institute, Boston. https://doi.org/10.1200/JCO.1988.6.10.1532 First Page PDF © 1988 by American Society of Clinical Oncology
Midline Cyst of the Prostate Mimicking Malignancy on FDG PET/CT
Authors: Dae-Weung Kim, Sang-Ah Jung, Soon-Ah Park, Chang Guhn Kim
Journal: Clinical Nuclear Medicine (2010)

A 58-years-old man underwent F-18 FDG PET/CT for health screening. F-18 FDG PET/CT revealed a focal, round, and 1.5 cm-sized hypermetabolic lesion at midline of the prostate. The lesion was suspected as a urinary activity or malignancy. On the review of medical records, it was found that the patient had undergone contrast-enhanced abdominal CT scan 1 day before PET/CT examination. On the attenuation-uncorrected image, the prostatic lesion was still evident. The lesion was considered as a midline cyst of prostate, communicating with urethra. It is suggested that radioactive urine remained in midline cyst resulting in the focal hypermetabolic lesion.
Prevention of Colorectal Cancer by Colonoscopic Polypectomy
Authors: Sidney J. Winawer, Ann G. Zauber, May Nah Ho, Michael J. O'Brien, Leonard S. Gottlieb, Stephen S. Sternberg, Jerome D. Waye, Melvin Schapiro, John H. Bond, Joel F. Panish, Frederick Ackroyd, Moshe Shike, Robert C. Kurtz, Lynn Hornsby-Lewis, Hans Gerdes, Edward T. Stewart
Journal: New England Journal of Medicine (1993)

The current practice of removing adenomatous polyps of the colon and rectum is based on the belief that this will prevent colorectal cancer. To address the hypothesis that colonoscopic polypectomy reduces the incidence of colorectal cancer, we analyzed the results of the National Polyp Study with reference to other published results.
Abstract P4-06-18: Asporin Is Associated with Invasive Growth and Bone Metastasis of Breast Cancer
Authors: J Bouchal, D Simkova, G. Kharaishvili
Journal: Cancer Research (2010)

Abstract Background: In an earlier publication we identified asporin as a novel cancer related protein (BMC Cancer 2007, 7:55), also reported among bone metastasis specific genes (Cancer Letters 2009, 276:212-220). Asporin is a member of the class I small leucine-rich repeat proteoglycan family and besides affinity to collagen, it binds calcium and initiates collagen mineralization. Asporin is abundantly expressed in tissues with high remodeling rate (e.g. peridontal ligament) whereas extremely high turnover of matrix proteins is also associated with invasive cancer. Material and methods: Formalin-fixed paraffin-embedded tissues [invasive ductal (101) and lobular (39) carcinomas classified according to hormone receptors and Her-2; 5 bone metastases from autopsies] were immunohistochemically stained with in-house polyclonal peptide antibody against asporin. The antibody was validated on uterus tissue as a positive control together with a commercial antibody (Abcam). Data were evaluated by non-parametric Mann-Whitney U test and Spearman correlation coefficient. Expression of asporin in both tissues and cell lines was also queried in databases Gene Expression Omnibus, ArrayExpress and Oncomine. Expression of asporin was further tested by RT-PCR in selected breast cancer cell lines. Migration and invasion of MDA-MB-231 cells were tested using real-time cell analysis Xcelligence system (Roche). Transwells were coated by solidifying collagen for 6 hours (with or without recombinant asporin). Starved cells were seeded on the collagen in transwells while FBS was used as a chemoattractant in bottom wells. Results: Levels of asporin were significantly higher in invasive lobularcarcinomas than ductal ones (P&amp;lt;0.001). Asporin was also highly expressed in all bone metastases. Asporin expression positively correlated with tumor grade within the triple negative subgroup (Rs 0.4, P&amp;lt;0.05) but not in luminal and Her-2 subtypes. Expression of asporin in invasive breast carcinomas was also confirmed in other public datasets (e.g. Karnoub breast and Hess breast in Oncomine database). Surprisingly, we found no breast cancer cell line overexpressing asporin, which underlines the importance of the tumor microenvironment in vivo. MDA-MB-231 cells migrated faster through collagen I with recombinant asporin. Conclusion: Asporin is expressed by both invasive breast carcinomas and bone metastases. Mechanistically, asporin may affect extracellular matrix structure and promote invasive growth of breast cancer cells. Further investigation of the role of asporin in metastasizing to bone is additionally justified given its affinity for calcium. Acknowledgements This work was supported by grants NS 9956-4 from the Czech Ministry of Health and MSM 6198959216 from the Czech Ministry of Education. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-06-18.
THU0214 Influence of Concomitant Methotrexate and Prednisolone Dose on Drug Inefficacy of Etanercept and Adalimumab in Patients with Rheumatoid Arthritis
Authors: K. Ebina, K. Shi, T. Tomita, Y. Kunugiza, Y. Hishitani, T. Hirano, A. Ogata, H. Yoshikawa
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In treating RA patients with etanercept (ETN) or adalimumab (ADA), influence of concomitant disease-modifying antirheumatic drugs (DMARDs) (methotrexate [MTX], bucillamine, salazosulfapyridine, tacrolimus, and mizolibin) and prednisolone (PSL) on biologic inefficacy still remains controversial. <h3>Objectives</h3> The objective of this study is to compare the effect of DMARDs and PSL on biologic inefficacy of ETN and ADA, and to investigate the index of subcutaneous anti-TNF biologics selection in RA patients. <h3>Methods</h3> 284 RA patients who were followed-up more than 6 months after starting ETN (184 patients / 164 female 20 male / age 55.3y / disease duration 9.5y / pre DAS28-CRP 4.1 / 1<sup>st</sup> Bio 148 / 2<sup>nd or later</sup> Bio 36) or ADA (100 patients / 87 female 13 male / age 51.6y / disease duration 9.9y / pre DAS28-CRP 4.2 / 1<sup>st</sup> Bio 60 / 2<sup>nd or later</sup> Bio 40) were enrolled, and correlation between biologic inefficacy and clinical parameters including concomitant DMARDs and PSL were evaluated. <h3>Results</h3> Drug inefficacy was monitored in 20.7% of ETN (1<sup>st</sup> Bio 16.9% / 2<sup>nd or later</sup> Bio 36.1%) and 28.0% of ADA (1<sup>st</sup> Bio 21.7% / 2<sup>nd or later</sup> Bio 37.5%) (ETN vs. ADA; P=0.16). Mean treatment continuation duration was 32.9 months in ETN (inefficacy group 21.6 months vs. efficacy group 42.7 months) and 15.5 months in ADA (inefficacy group 9.8 months vs. efficacy group 20.8 months), and treatment continuation duration of inefficacy group was significantly longer in ETN compared to ADA (P&lt;0.01). In ETN, inefficacy group showed higher dose of concomitant PSL (7.0 vs. 4.4 mg/day; P&lt;0.001) and higher pre DAS28-CRP (4.5 vs. 4.1; P&lt;0.05) compared to efficacy group. In ADA, inefficacy group showed lower dose of concomitant MTX (4.6 vs. 7.0 mg/week; P&lt;0.01) and higher pre DAS28-CRP (4.5 vs. 3.9; P&lt;0.01) compared to efficacy group. As for concomitant dose of MTX, when treated less than 6mg/week, inefficacy rate was significantly higher in ADA (36.5%) compared to ETN (21.0%) (P&lt;0.05). However, those who were treated more than 8mg/week MTX, inefficacy rate was similar (ETN 19.0% vs. ADA 18.8%). In ETN, inefficacy rate was 8.2% when concomitant PSL was ≤4mg/day, while it was significantly higher (28.8%) in those who were treated more than ≥5mg/day PSL (P&lt;0.001). PSL showed no significant correlation with inefficacy rate of ADA. Age, sexuality, body mass index, duration of disease, and dose of other DMARDs did not show any significant correlation with inefficacy rate of ETN and ADA. <h3>Conclusions</h3> When choosing ETN or ADA in the treatment of RA, concomitant MTX ≥8mg/week or PSL ≥5mg/day should be taken into consideration to avoid drug inefficacy. <h3>Disclosure of Interest</h3> None Declared
FRI0422 Successful dose reduction of tnf-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity
Authors: S. Arends, E. van der Veer, F. B. Kamps, M. Efde, M. K. Leijsma, H. Bootsma, E. Brouwer, A. Spoorenberg
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). <h3>Objectives</h3> In view of the high costs and possible side effects, our aim was to investigate whether dose reduction of TNF-α blocking agents is possible without loss of effectiveness in AS patients in daily clinical practice. <h3>Methods</h3> Patients included in the Groningen Leeuwarden AS (GLAS) cohort with active disease (Bath AS disease activity index (BASDAI)≥4) before start of anti-TNF-α treatment and stable (≥6 months) low disease activity (BASDAI&lt;4) on conventional dose regime, who started with dose reduction were studied. Data concerning medication dose, reasons for changing medication dose, and disease activity were collected after 6, 12, 18, and 24 months of dose reduction. <h3>Results</h3> Between November 2005 and January 2011, 49 AS patients with stable low disease activity started with dose reduction of infliximab (n=8), etanercept (n=35), or adalimumab (n=6). 88% of these patients were male, mean age was 46 years (SD±12), and mean duration of symptoms was 20 years (SD±10). Mean BASDAI was 1.8 (SD±1.1) at start of dose reduction, coming from 6.2 (SD±1.2) just before start of anti-TNF-α treatment. In total, 71%, 54%, 47%, and 42% of the patients maintained on dose reduction after 6, 12, 18 and 24 months, respectively. The mean dose reduction was 37% (SD±11). Disease activity remained low (BASDAI&lt;4) in 86% of the patients who continued dose reduction at 24 months (Table 1). <h3>Conclusions</h3> In this observational cohort, long-term dose reduction of TNF-α blocking agents was possible preserving low disease activity in a substantial number of AS patients. <h3>Disclosure of Interest</h3> None Declared
Discordance of Erbb2 Expression in the Primary Tumor and Its Lymph Node Metastases in Gastric Cancer
Authors: Fatih Selcukbiricik, Sibel Erdamar, Deniz Tural, Fuat Demirelli, Evin Buyukunal, Suheyla Serdengecti
Journal: Annals of Oncology (2013)
Localization of Parathyroid Adenoma by 11C-Choline PET/CT
Authors: Marina Orevi, Nanette Freedman, Eyal Mishani, Moshe Bocher, Orit Jacobson, Yodphat Krausz
Journal: Clinical Nuclear Medicine (2014)

This prospective pilot study was aimed to evaluate ¹¹C-choline PET/CT (choline) as a tool for localization of parathyroid adenoma (PTA).Forty patients with biochemical hyperparathyroidism underwent choline and ⁹⁹mTc-MIBI imaging within a median interval of 56 days. Choline and MIBI images were analyzed and correlated with each other, with additional modalities such as ultrasound, CT, MRI, and with surgical findings, when available.Thirty-seven of forty cases were choline-positive, and 3 were choline-negative. Choline uptake on PET was identified with corresponding nodules on CT of the PET/CT, yielding precise localization. Twenty of thirty-seven foci were located in typical sites in the neck, and 17 were ectopic. Clear visualization of PTA was achieved in 33 of 37, whereas findings in 4 cases were suspicious for PTA. MIBI was positive in 33 of 40 cases (22 clearly positive, 11 suspicious). In 29 of 40 cases, choline and MIBI were concordant, but choline findings were clearer in 9 of these 29 studies.At the time of writing, 27 patients had undergone surgery. In 24 cases, there was complete matching of choline with surgical findings of PTA. Overall in 23 cases, both choline and MIBI matched surgical findings of PTA. In 1 case, PTA was correctly localized on choline but not on MIBI, and in 2 cases, neither choline nor MIBI corresponded to the surgical findings.These preliminary results indicate that the combined functional and anatomical modality of choline PET/CT is a promising tool for PTA localization, providing clearer images than MIBI, equal or better accuracy, and quicker and easier acquisition.
AB0249 Audit on awareness and uptake of influenza and pneumococcal vaccines in rheumatology outpatients
Authors: P. Shrestha
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatology patients with autoimmune inflammatory rheumatic diseases on major DMARDs and/or biologics are at increased risk of infection because of ill-defined immunoregulatory state as well as immunosuppressive drugs. Vaccination against Influenza and Pneumococcus is recommended for such patients<sup>1</sup>. <h3>Objectives</h3> Our ain was to study the awareness and uptake of these vaccines in our rheumatology outpatient cohort on major immunosuppressive drugs and/or biologics. <h3>Methods</h3> We audited a total of 60 patients attending our rheumatology outpatient clinics and on major DMARDs (n=29) and/or biologics (n=31). Data collection was done by pre-printed clinical questionnaire during clinic visits. Data was collected on demographics, underlying diagnosis, DMARD/biologics/steroids used, other co-morbid risk factors like Diabetes, chronic lung and heart disease, age over 65 and renal failure, and on awareness and uptake rates of both vaccines. <h3>Results</h3> 29 patients were on major DMARDS alone while 31 were on biologics. Although the awareness for vaccination was high at 83%, only 72% had influenza vaccination in the last year and 40% had Pneumococcal vaccination. Even in patients with additional risk factors like Diabetes, chronic lung or heart disease, age over 65 years etc, Pneumococcal vaccination uptake was only 28% compared to 87% for influenza vaccine. The main reasons for low uptake of pneumococcal vaccine were non-availability of Pneumovax for such patients at general practice and patient refusal due to previous reaction. <h3>Conclusions</h3> There is good uptake of Influenza vaccine in our rheumatology cohort on major DMARDs/Biologics. The uptake of pneumococccal vaccine is sub-optimal even in those immunosuppressed patients with additional risk factors. Raising awareness about the importance and safety of such vaccinations amongst patients and local general practitioners and improving availability of such vaccines at primary care level is of paramount importance to help reduce recurrent serious infections and hospitalisations. <h3>References</h3> <i>van Assen, S;Agmon-Levin, N et al EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnn Rheum Dis 2011;70:414-422 doi:10.1136/ard.2010.137216</i> <h3>Disclosure of Interest</h3> None Declared